Cargando…

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users

Understanding the factors involved in the development of broadly neutralizing antibody (bNAb) responses in natural infection can guide vaccine design aimed at eliciting protective bNAb responses. Most of the studies to identify and study the development of bNAb responses have been performed in indiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	EULER, Zelda, VAN DEN KERKHOF, Tom L., KOUYOS, Roger D., TULLY, Damien C., ALLEN, Todd M., TRKOLA, Alexandra, SANDERS, Rogier W., SCHUITEMAKER, Hanneke, VAN GILS, Marit J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521154/ https://www.ncbi.nlm.nih.gov/pubmed/31027215 http://dx.doi.org/10.3390/v11040384

Ejemplares similares

HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients
por: van den Kerkhof, Tom, et al.
Publicado: (2011)

Cross-reactive broadly neutralizing antibodies: timing is everything
por: Euler, Zelda, et al.
Publicado: (2012)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

Cross-reactive neutralizing activity in HIV-1 infected injecting drug users
por: Euler, Z, et al.
Publicado: (2012)

Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals
por: Euler, Zelda, et al.
Publicado: (2013)

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity
por: van den Kerkhof, Tom L G M, et al.
Publicado: (2013)

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds
por: van den Kerkhof, Tom L. G. M., et al.
Publicado: (2016)

HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals
por: van den Kerkhof, TL, et al.
Publicado: (2012)

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice
por: van der Velden, Yme U., et al.
Publicado: (2020)

Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention
por: Wagh, Kshitij, et al.
Publicado: (2021)

HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans
por: Malherbe, Delphine C., et al.
Publicado: (2013)

Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies
por: Yuan, Meng, et al.
Publicado: (2019)

Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers
por: Schorcht, Anna, et al.
Publicado: (2020)

Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
por: van Schooten, Jelle, et al.
Publicado: (2022)

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
por: Schommers, Philipp, et al.
Publicado: (2020)

The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization
por: Schorcht, Anna, et al.
Publicado: (2022)

Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
por: Subbaraman, Harini, et al.
Publicado: (2018)

HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth
por: van Schooten, Jelle, et al.
Publicado: (2018)

Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization
por: Friedrich, Nikolas, et al.
Publicado: (2021)

Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody
por: Heydarchi, Behnaz, et al.
Publicado: (2022)

A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
por: Sanders, Rogier W., et al.
Publicado: (2013)

Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent
por: Reh, Lucia, et al.
Publicado: (2015)

Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual
por: Guerra, Denise, et al.
Publicado: (2023)

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface
por: Huang, Jinghe, et al.
Publicado: (2014)

CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity
por: Ivan, Branislav, et al.
Publicado: (2019)

Signatures of V(H)1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteins
por: Capella-Pujol, Joan, et al.
Publicado: (2023)

Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity
por: Kadelka, Claus, et al.
Publicado: (2018)

Inactivated Viral Vaccines
por: Sanders, Barbara, et al.
Publicado: (2014)

Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage
por: Reh, Lucia, et al.
Publicado: (2018)

Structural basis for broad coronavirus neutralization
por: Sauer, Maximilian M., et al.
Publicado: (2021)

Natural infection as a blueprint for rational HIV vaccine design
por: van Haaren, Marlies M., et al.
Publicado: (2016)

A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike
por: van der Velden, Yme U., et al.
Publicado: (2022)

Assessing immunogenicity barriers of the HIV-1 envelope trimer
por: Maliqi, Liridona, et al.
Publicado: (2023)

Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity
por: Liu, Hejun, et al.
Publicado: (2020)

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
por: Liu, Hejun, et al.
Publicado: (2020)

Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
por: Bajic, Goran, et al.
Publicado: (2019)

Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation
por: van der Straten, Karlijn, et al.
Publicado: (2022)

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
por: Schriek, Angela I., et al.
Publicado: (2022)

Broadly Neutralizing Antibodies for HIV Eradication
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8h6ek3gsiqhqfrpdtsc772e45d